Postpartum hemorrhage
Drug research and approvals for postpartum hemorrhage: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 38 studies of postpartum hemorrhage are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 38
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Long Term Outcome After Use of Vacuum-induced Tamponade for Postpartum HemorrhageNCT07885072 · Not reported · University of Zurich · starts Oct 1, 2026
- Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal DeliveryNCT07714902 · Not applicable · Rambam Health Care Campus · starts Jun 24, 2026
- Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority TrialNCT07636421 · Phase 4 · Mansoura University · starts Aug 8, 2026
- Prediction of Platelet Function Using Viscoelastic Test (ROTEM® Sigma) in Obstetric Anesthesia.NCT07616349 · Not reported · Nicolas Brogly · starts May 1, 2026
- Effect of Simulation-Based Postpartum Hemorrhage Training on Team Performance in Senior Anesthesiology TeamsNCT07519252 · Not applicable · Mehmet Kırıköz · starts Jul 24, 2026
- Hemophilia A Research ProgramNCT07414511 · Not reported · University of Washington · starts Jul 31, 2024
- Umbilical Cord Drainage to Prevent Postpartum HemorrhageNCT07401160 · Not applicable · Universidad Nacional Autonoma de Honduras · starts Feb 15, 2026
- Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum HemorrhageNCT07401524 · Phase 4 · Sheba Medical Center · starts May 5, 2026
- Topical Tranexamic Acid to Reduce Blood Loss During Cesarean DeliveryNCT07362992 · Early Phase 1 · Wolfson Medical Center · starts Jul 1, 2026
Approved 1
- CarboprostProstanoid FP receptor agonist
Phase 3 7
- OxytocinOxytocin receptor agonist
- Tranexamic acidPlasminogen inhibitor
- MisoprostolProstanoid EP3 receptor agonist
- CarbetocinOxytocin receptor agonist
- Ergonovine
- Iron isomaltoside 1000Supplement
- Von willebrand factor humanvon Willebrand factor exogenous protein
Phase 2 3
- Fibrinogen, humanFibrinogen exogenous protein
- RanitidineHistamine H2 receptor antagonist
- Dextrose
Phase 1 or earlier 4
- MoxifloxacinTopoisomerase IV inhibitor
- MelatoninMelatonin receptor agonist
- Dobesilic acid
- Ascorbic acidSupplement
How its trials ended
390 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 76 whose ending is known, 45% met their primary endpoint, 24% missed it and 32% stopped early.
- Completed, result not reported19650%
- Status unknown6817%
- Ongoing5013%
- Met its primary endpoint349%
- Missed its primary endpoint185%
- Stopped: other or unclear185%
- Stopped: enrollment or feasibility31%
- Stopped: lack of efficacy21%
- Stopped: funding1<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 20, 2022 | Human recombinant factor VIIa variant (P10Q, K32E, T106N,…Treatment of postpartum hemorrhage | Coagulant Therapeutics, Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA